SEC Comment Letter for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883) (BCLI) — Jul 21, 2014
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883)
Date: July 21, 2014 · CIK: 0001137883 · Accession: 0000000000-14-036629
AI Filing Summary & Sentiment
Reasoning
Letter
July 21, 2014 Via E -mail Liat Sossover Chief Financial Officer Brainstorm Cell Therapeutics Inc. 605 Third Avenue, 34th Floor New York, NY 10158
Re: Brainstorm Cell Therapeutics Inc. Preliminary Proxy Statement on Schedule 14A Filed July 10, 2014 File No. 000 -54365
Dear Ms. Sossover :
We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Daniel Greenspan for
Show Raw Text
July 21, 2014 Via E -mail Liat Sossover Chief Financial Officer Brainstorm Cell Therapeutics Inc. 605 Third Avenue, 34th Floor New York, NY 10158 Re: Brainstorm Cell Therapeutics Inc. Preliminary Proxy Statement on Schedule 14A Filed July 10, 2014 File No. 000 -54365 Dear Ms. Sossover : We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Daniel Greenspan for Jeffrey P. Rie dler Assistant Director